Current strategies to prevent transmission of prions by human plasma derivatives

T. Burnouf, A. Padilla

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Protein products prepared from pooled human plasma are an essential class of therapeutics used mostly to control bleeding and/or immunological disorders. Because of the human origin of the starting material, there is a risk that these products may possibly transmit prions causing variant Creutzfeldt-Jakob disease (vCJD). No case of transmission of prions by plasma products has been observed. Case-by-case measures implemented in various countries, and several technical factors may contribute, to various degrees, to the prevention of the risk of transmission of prions by plasma products. Those measures include (a) the epidemiological surveillance of population in countries with cases of vCJD and/or bovine spongiform encephalopathies (BSE), (b) the deferral of blood donors who traveled or resided, for specific periods of time, to countries with BSE, or who received transfusion or tissue transplant, (c) the removal of leucocytes in plasma used for fractionation, and, last but not least, (d) the removal of the prion agents during the complex industrial fractionation process used to prepare plasma products. Numerous experimental infectivity studies, involving the spiking of brain-derived infectious materials, have demonstrated that several fractionation steps, in particular ethanol fractionation, depth filtration, and chromatography, can remove several logs of prions. Removal is explained by the distinct hydrophobic and aggregative properties of the prion proteins. In addition, nanofiltration using multi-layer membranes of 75 nm or smaller, which is commonly used for removing viruses from coagulation factors and immunoglobulins products, can remove more than 3-5 logs of spiked prions, presumably by size-exclusion and trapping mechanisms. Therefore, the risk of transmission of vCJD by human plasma products appears remote, but caution should prevail since the biochemical nature of the infectious agent in human blood is still unknown.

Original languageEnglish
Pages (from-to)320-328
Number of pages9
JournalTransfusion Clinique et Biologique
Volume13
Issue number5
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

Fingerprint

Prions
Fractionation
Derivatives
Plasmas
Creutzfeldt-Jakob Syndrome
Bovine Spongiform Encephalopathy
Plasma (human)
Blood
Population Surveillance
Nanofiltration
Transplants
Blood Coagulation Factors
Chromatography
Blood Donors
Viruses
Immunoglobulins
Brain
Leukocytes
Ethanol
Tissue

Keywords

  • Fractionation
  • Plasma products
  • Prions
  • PrP
  • Safety
  • vCJD

ASJC Scopus subject areas

  • Hematology

Cite this

Current strategies to prevent transmission of prions by human plasma derivatives. / Burnouf, T.; Padilla, A.

In: Transfusion Clinique et Biologique, Vol. 13, No. 5, 11.2006, p. 320-328.

Research output: Contribution to journalArticle

@article{dbb7a595ef4c4823acce6a8706dacc8c,
title = "Current strategies to prevent transmission of prions by human plasma derivatives",
abstract = "Protein products prepared from pooled human plasma are an essential class of therapeutics used mostly to control bleeding and/or immunological disorders. Because of the human origin of the starting material, there is a risk that these products may possibly transmit prions causing variant Creutzfeldt-Jakob disease (vCJD). No case of transmission of prions by plasma products has been observed. Case-by-case measures implemented in various countries, and several technical factors may contribute, to various degrees, to the prevention of the risk of transmission of prions by plasma products. Those measures include (a) the epidemiological surveillance of population in countries with cases of vCJD and/or bovine spongiform encephalopathies (BSE), (b) the deferral of blood donors who traveled or resided, for specific periods of time, to countries with BSE, or who received transfusion or tissue transplant, (c) the removal of leucocytes in plasma used for fractionation, and, last but not least, (d) the removal of the prion agents during the complex industrial fractionation process used to prepare plasma products. Numerous experimental infectivity studies, involving the spiking of brain-derived infectious materials, have demonstrated that several fractionation steps, in particular ethanol fractionation, depth filtration, and chromatography, can remove several logs of prions. Removal is explained by the distinct hydrophobic and aggregative properties of the prion proteins. In addition, nanofiltration using multi-layer membranes of 75 nm or smaller, which is commonly used for removing viruses from coagulation factors and immunoglobulins products, can remove more than 3-5 logs of spiked prions, presumably by size-exclusion and trapping mechanisms. Therefore, the risk of transmission of vCJD by human plasma products appears remote, but caution should prevail since the biochemical nature of the infectious agent in human blood is still unknown.",
keywords = "Fractionation, Plasma products, Prions, PrP, Safety, vCJD",
author = "T. Burnouf and A. Padilla",
year = "2006",
month = "11",
doi = "10.1016/j.tracli.2006.11.001",
language = "English",
volume = "13",
pages = "320--328",
journal = "Transfusion Clinique et Biologique",
issn = "1246-7820",
publisher = "Elsevier Masson",
number = "5",

}

TY - JOUR

T1 - Current strategies to prevent transmission of prions by human plasma derivatives

AU - Burnouf, T.

AU - Padilla, A.

PY - 2006/11

Y1 - 2006/11

N2 - Protein products prepared from pooled human plasma are an essential class of therapeutics used mostly to control bleeding and/or immunological disorders. Because of the human origin of the starting material, there is a risk that these products may possibly transmit prions causing variant Creutzfeldt-Jakob disease (vCJD). No case of transmission of prions by plasma products has been observed. Case-by-case measures implemented in various countries, and several technical factors may contribute, to various degrees, to the prevention of the risk of transmission of prions by plasma products. Those measures include (a) the epidemiological surveillance of population in countries with cases of vCJD and/or bovine spongiform encephalopathies (BSE), (b) the deferral of blood donors who traveled or resided, for specific periods of time, to countries with BSE, or who received transfusion or tissue transplant, (c) the removal of leucocytes in plasma used for fractionation, and, last but not least, (d) the removal of the prion agents during the complex industrial fractionation process used to prepare plasma products. Numerous experimental infectivity studies, involving the spiking of brain-derived infectious materials, have demonstrated that several fractionation steps, in particular ethanol fractionation, depth filtration, and chromatography, can remove several logs of prions. Removal is explained by the distinct hydrophobic and aggregative properties of the prion proteins. In addition, nanofiltration using multi-layer membranes of 75 nm or smaller, which is commonly used for removing viruses from coagulation factors and immunoglobulins products, can remove more than 3-5 logs of spiked prions, presumably by size-exclusion and trapping mechanisms. Therefore, the risk of transmission of vCJD by human plasma products appears remote, but caution should prevail since the biochemical nature of the infectious agent in human blood is still unknown.

AB - Protein products prepared from pooled human plasma are an essential class of therapeutics used mostly to control bleeding and/or immunological disorders. Because of the human origin of the starting material, there is a risk that these products may possibly transmit prions causing variant Creutzfeldt-Jakob disease (vCJD). No case of transmission of prions by plasma products has been observed. Case-by-case measures implemented in various countries, and several technical factors may contribute, to various degrees, to the prevention of the risk of transmission of prions by plasma products. Those measures include (a) the epidemiological surveillance of population in countries with cases of vCJD and/or bovine spongiform encephalopathies (BSE), (b) the deferral of blood donors who traveled or resided, for specific periods of time, to countries with BSE, or who received transfusion or tissue transplant, (c) the removal of leucocytes in plasma used for fractionation, and, last but not least, (d) the removal of the prion agents during the complex industrial fractionation process used to prepare plasma products. Numerous experimental infectivity studies, involving the spiking of brain-derived infectious materials, have demonstrated that several fractionation steps, in particular ethanol fractionation, depth filtration, and chromatography, can remove several logs of prions. Removal is explained by the distinct hydrophobic and aggregative properties of the prion proteins. In addition, nanofiltration using multi-layer membranes of 75 nm or smaller, which is commonly used for removing viruses from coagulation factors and immunoglobulins products, can remove more than 3-5 logs of spiked prions, presumably by size-exclusion and trapping mechanisms. Therefore, the risk of transmission of vCJD by human plasma products appears remote, but caution should prevail since the biochemical nature of the infectious agent in human blood is still unknown.

KW - Fractionation

KW - Plasma products

KW - Prions

KW - PrP

KW - Safety

KW - vCJD

UR - http://www.scopus.com/inward/record.url?scp=33846700716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846700716&partnerID=8YFLogxK

U2 - 10.1016/j.tracli.2006.11.001

DO - 10.1016/j.tracli.2006.11.001

M3 - Article

C2 - 17254822

AN - SCOPUS:33846700716

VL - 13

SP - 320

EP - 328

JO - Transfusion Clinique et Biologique

JF - Transfusion Clinique et Biologique

SN - 1246-7820

IS - 5

ER -